Cholestasis is a common manifestation of liver disease. Cholestasis often is due to disorders specifically affecting cholangiocytes, which play a major role in bile secretion. They are responsible for secretion of bicarbonate into bile and modulating the biliary contents of other constituents as well. The type III inositol trisphosphate receptor (InsP3R-3) is the primary intracellular calcium release channel in cholangiocytes and our previous studies have shown that apically-localized InsP3R-3 controls bicarbonate secretion. We also found that in most ductular forms of human cholestasis and in multiple animal models, there is loss of InsP3R-3 expression, underlying the importance of calcium homeostasis in normal cholangiocyte function and its dysregulation in cholestasis. We hypothesize that restoration of InsP3R-3 expression will ameliorate cholestasis and improve biliary bicarbonate secretion. Thus the long term objective of this grant is to understand the molecular mechanisms of InsP3R-3 regulation in normal and cholestatic liver and the therapeutic effect of restoration of InsP3R- 3 expression on liver function. To achieve this objective, the proposal will be implemented with the following specific aims: (1) The molecular factors governing the regulation of InsP3R-3 gene expression will be defined by studying the transcription factors (TFs) and microRNAs (miRs) that regulate the InsP3R-3 promoter and mRNA respectively; (2) The cellular mechanisms that direct InsP3R-3 to the subapical region of cholangiocytes including targeting sequences and interacting proteins that lead to such localization will be established; (3) Molecular mechanisms that lead to loss of InsP3R-3 expression and function in animal/human models of cholestasis (including InsP3R-3 KO mice and CRISPR/Cas9-InsP3R-3-null human cholangiocytes) will be determined and verified in human cholestatic liver. Further, we will investigate whether restoration of expression-specific TFs/miRs-anti-miRs in cholestasis results in improvement of disease. Together, the data derived from these studies will improve our understanding of the regulation of secretion in cholangiocytes, and have the potential to lead to design of novel therapeutic approaches for the treatment of cholestatic disorders.

Public Health Relevance

Cholestasis results from disorders including gallstones, biliary atresia, genetic mutations, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), and is a frequent cause of liver fibrosis and cirrhosis in US requiring liver transplantation. This research proposal will investigate the basic biological mechanisms responsible for the deranged liver function during cholestasis. Novel concepts and studies described in this grant proposal will result in identification of new targets for drug development to treat this class of liver diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK112797-01A1
Application #
9446684
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Burgess-Beusse, Bonnie L
Project Start
2018-05-15
Project End
2022-04-30
Budget Start
2018-05-15
Budget End
2019-04-30
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Franca, Andressa; Filho, Antonio Carlos Melo Lima; Guerra, Mateus T et al. (2018) Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes. Hepatology :